<?xml version="1.0" encoding="UTF-8"?>
<BillSummaries>
<item congress="113" measure-type="s" measure-number="2338" measure-id="id113s2338" originChamber="SENATE" orig-publish-date="2014-05-14" update-date="2014-12-22">
<title>United States Anti-Doping Agency Reauthorization Act</title>
<summary summary-id="id113s2338v49" currentChamber="BOTH" update-date="2014-12-22">
<action-date>2014-12-18</action-date>
<action-desc>Public Law</action-desc>
<summary-text><![CDATA[<p><b>(This measure has not been amended since it was introduced. The summary of that version is repeated here.)</b></p> <p>United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.</p>]]></summary-text>
</summary>
<summary summary-id="id113s2338v81" currentChamber="HOUSE" update-date="2014-12-22">
<action-date>2014-12-12</action-date>
<action-desc>Passed House without amendment</action-desc>
<summary-text><![CDATA[<p><b>(This measure has not been amended since it was introduced. The summary of that version is repeated here.)</b></p> <p>United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.</p>]]></summary-text>
</summary>
<summary summary-id="id113s2338v82" currentChamber="SENATE" update-date="2014-12-22">
<action-date>2014-12-11</action-date>
<action-desc>Passed Senate without amendment</action-desc>
<summary-text><![CDATA[<p><b>(This measure has not been amended since it was introduced. The summary of that version is repeated here.)</b></p> <p>United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.</p>]]></summary-text>
</summary>
<summary summary-id="id113s2338v80" currentChamber="SENATE" update-date="2014-12-05">
<action-date>2014-12-01</action-date>
<action-desc>Reported to Senate without amendment</action-desc>
<summary-text><![CDATA[<p><b>(This measure has not been amended since it was introduced. The summary of that version is repeated here.)</b></p> <p>United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.</p>]]></summary-text>
</summary>
<summary summary-id="id113s2338v00" currentChamber="SENATE" update-date="2014-08-22">
<action-date>2014-05-14</action-date>
<action-desc>Introduced in Senate</action-desc>
<summary-text><![CDATA[<p>United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.</p>]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
